Six Clinics in Eighteen Months, No Pipeline

Build it from demand, not from headcount ratios.

1. Demand model: per clinic, staffing required by role by month, accounting for ramp (a new clinic typically needs a full complement at opening, not at steady state). Include the volume assumptions the growth plan is already using.
2. Supply model: current headcount, minus projected attrition (apply 34% to MAs and a role-specific rate to NPs, not a blended average), plus expected internal promotions, minus known departures. Net the two to get a gap by role by quarter.
3. Feasibility check: convert the gap into hiring requirements per month. If the plan needs, say, 22 new MAs in 18 months and 9 NPs, ask whether the recruiting function can source that against a 120-day NP cycle and what the market supply is. A 120-day cycle against a 6-month backlog means the NP gap must be closed before site openings, not after.

What must be established before agreement. Is the 18-month schedule fixed by lease commitments, payer contracts, or by executive ambition? That single answer determines whether the workforce plan serves the growth plan or jointly reshapes it. HR's job is to put the arithmetic in front of the executive team in a way that makes the trade-off explicit - for example, 'the schedule is achievable for four sites on current supply assumptions; six is achievable if we fund an MA training pipeline and accept premium pay for NPs in year one, or if two openings slip a quarter.'

Build the cost comparison the board actually needs. The $2.1M agency spend is the current price of the gap. Compare the projected cost of the plan to the projected cost of doing nothing, since the status quo is already on the P&L.

Buy - targeted, not across the board. A selective market adjustment for medical assistants to remove the most acute compression, funded by reallocating merit from roles at or above market. Redirecting roughly 1–1.5 points of the 2.5% pool toward MA market movement will not close 8%, but it will narrow the gap enough to reduce the share of exits attributed to pay. Pair it with a defined differentiation mechanism (tenure plus performance) rather than a flat increase, so the money buys retention instead of just raising the baseline. NP pay is a separate and harder problem: pay for the role, not the person, and be honest that premium pay for hard-to-fill sites is cheaper than perpetuating agency spend.

Build - the highest-leverage move. Launch a structured MA training pathway with the community college (externships converting to hires, a paid 6–10 week preceptor program, a service commitment). This addresses 34% turnover and the gap simultaneously, and it changes the supply curve rather than competing for a fixed pool. It also creates an internal promotion route into other clinical roles, which is itself a retention lever. Realistic lead time: 6–9 months to first cohort hire. Because that exceeds the opening timeline for the first new sites, it cannot be the year-one answer alone - sequence it as the year-two fix while buying year-one.

Borrow - bounded and explicit. Contract labor for the opening surge, capped at a defined dollar amount and tied to a specific site and date, with a written exit condition. Unbounded agency use is what produced the $2.1M. Also consider reciprocal coverage across clinics and flexible scheduling for existing staff, which borrows capacity from within before borrowing from the market.

Defense to the board. Frame as a portfolio: buy to stop the bleeding now, build to change the structural supply over 18–36 months, borrow to bridge the unavoidable gap, with each leg carrying a cost ceiling and a sunset condition. The defensible claim is not that this fully closes the gap - it is that it converts an uncontrolled $2.1M agency line into a bounded, declining investment.

Metrics (monthly, rolled quarterly).

• Vacancy rate and average days-to-fill by role, weighted by revenue impact - not a blended company average.
• First-year MA turnover separately from overall MA turnover; the first-year number tells you whether the problem is selection or the job.
• Agency spend as a percentage of total clinical labor, with a target trajectory, not just an actual.
• Internal fill rate and promotions into clinical roles (the build strategy's leading indicator).
• Cohort metrics: externs offered, externs converted, 6-month retention of converted hires.
• Cost per hire and offer acceptance rate by role, which reveal whether pay positioning is losing candidates at the offer stage.

Top three risks.

1. Opening schedule outruns supply. If sites open before staffing is secured, the result is agency dependency from day one and a quality-of-care exposure - a patient safety issue, not just a cost issue. Recommendation: a documented readiness gate per site tied to staffing thresholds.
2. Pay compression spillover. Adjusting MA pay without examining adjacent roles risks creating new internal equity problems and new turnover one level up. Conduct the equity review before the adjustment, not after.
3. The build strategy arrives too late and gets cut. Training programs are the first thing cut if year-one results disappoint. Protect it with a board-level commitment and a named executive owner (the VP of Clinical Operations, not HR), because the person accountable for openings must own the pipeline.

Also flag the owner gap. The VP of Clinical Operations is focused on schedule. The workforce plan needs one executive who owns its success and is measured on it; otherwise it becomes an HR document that the operating plan quietly overrides.